Trident Lifeline Limited (BSE: 543616) is a Surat, Gujarat-based company in the Pharmaceutical Contract Manufacturing Services industry. With a market capitalisation of ₹511 Cr, it ranks #1,995 by market cap among the 6,197 Indian listed companies on FinBizNet, and #8 of 26 in Pharmaceutical Contract Manufacturing Services. At ₹421.00 (as of 16 Nov 2026), the share price is 4.8% below its 52-week high of ₹442.00 and 83.1% above its 52-week low of ₹229.95. The share price is up 37.6% over one year and up 60.5% over three months.
| Current Price | ₹421.00 |
|---|---|
| Market Cap | ₹511 Cr |
| BSE Code | 543616 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Pharmaceutical Contract Manufacturing Services |
| P/E Ratio | 26 |
| Return on Assets | 7.31% |
| 52-Week Range | ₹229.95 – ₹442.00 |
| 1-Year Price Change | +37.6% |
| 3-Month Price Change | +60.5% |
| Beta (1Y) | 0.05 |
| Dividend Yield | 0.24% |
| Headquarters | Surat, Gujarat |
| Website | tridentlifeline.com |
Promoters held 73.68% of Trident Lifeline Limited's shares as of Jun 2026, unchanged from Jun 2025. Delivery averaged 79.7% of traded volume across 15 BSE sessions (21 Oct 2026 – 13 Nov 2026).
Trident Lifeline Limited, together with its subsidiaries, manufactures and markets finished doses in India, Ghana, Kenya, Peru, Cameroon, Venezuela, and internationally. The company offers various medicinal products, including pharmaceuticals, nutraceuticals, herbals, and injectables in the form of tablets, capsules, dry powders for oral suspension, oral liquids, ointments, liquid ointments, effervescent tablets, sachets, pastes, gels, solutions, suspensions, ice gels, syrups, and creams, as well as toothpaste and mouthwash. Its products target a range of therapeutic solutions, such as antibacterial, antidiarrheal, antifungal, antimalarial, antidiabetic, dental cure, proton pump inhibitor, antiprotozoal, antihistamine, antihypertensive drugs, antiparasitic, antilipidemic drugs, multivitamins, multiminerals, and non-steroidal anti-inflammatory drugs. The company is also involved in the manufacturing of formulations under proprietary brands; contract manufacturing arrangements; manufactu
1. Sale of Pharmaceuticals Products-This segment engages in the pharmaceutical business. Its product portfolio comprises of a range of drugs, such as anti-bacterial, anti-diarrheal, anti-fungal, anti-malarial, anti-diabetic, dental cure, proton pump inhibitor, anti-protozoal, anti-histamine, anti-hypertensive, anti-lipidemic, anti-parasitic, multivitamins, multimineral nyteraceuticals, and non-steroidal anti-inflammatory drugs. This segment is also involved in the distribution of pharmaceutical products. 2. NA-NA 3. NA-NA 4. NA-NA
1. Sale of Pharmaceuticals Products-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Torrent Pharma Ltd. | ₹1,79,494 Cr | 73.6 | 16.98% | ₹4,979 Cr | +30.4% |
| Aether Industries Limited | ₹21,710 Cr | 101.8 | 9.81% | ₹347 Cr | +127.8% |
| Alivus Life Sciences Ltd | ₹17,862 Cr | 31.5 | 18.36% | ₹682 Cr | +64.0% |
| Aarti Pharmalabs Ltd | ₹8,374 Cr | 52.5 | 8.49% | ₹610 Cr | +15.4% |
| Solara Active Pharma Sciences Limited | ₹3,225 Cr | n/m | -0.63% | ₹417 Cr | +22.1% |
| Sai Parenteral's Limited | ₹2,235 Cr | 115.8 | 2.88% | ₹195 Cr | — |
| KRM Ayurveda Limited | ₹521 Cr | 25.9 | 17.54% | ₹32 Cr | — |
| Trident Lifeline Limited | ₹511 Cr | 26 | — | — | +37.6% |
| Infinium Pharmachem Limited | ₹436 Cr | 36.4 | 10.54% | — | +11.7% |
Listed by market capitalisation. Ratios are shown for context only.
Trident Lifeline Limited is trading at ₹421.00, with a market capitalisation of ₹511 Cr.
Trident Lifeline Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Pharmaceutical Contract Manufacturing Services).
Trident Lifeline Limited has a P/E of 26.
Trident Lifeline Limited is listed on the BSE under the scrip code 543616.
Trident Lifeline Limited's share price is up 37.6% over one year and up 60.5% over three months. Its 52-week range is ₹229.95 to ₹442.00.
Promoters held 73.68% of Trident Lifeline Limited's shares as of Jun 2026, unchanged from Jun 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.